Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PUMA BIOTECHNOLOGY, INC.

(PBYI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Puma Biotech: Q2 Earnings Snapshot

08/05/2021 | 07:23pm EST

LOS ANGELES (AP) _ Puma Biotechnology Inc. (PBYI) on Thursday reported a second-quarter loss of $5.1 million, after reporting a profit in the same period a year earlier.

The Los Angeles-based company said it had a loss of 13 cents per share.

The biopharmaceutical company posted revenue of $53.4 million in the period.

Puma Biotech shares have decreased 32% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $6.99, a decline of 36% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PBYI at https://www.zacks.com/ap/PBYI

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about PUMA BIOTECHNOLOGY, INC.
12/03Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
BU
11/23Puma Biotechnology Gets 5-Year Extension for Key Nerlynx Patent
MT
11/23Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX« (neratinib)
BU
11/20Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 202..
BU
11/20Puma Biotechnology, Inc. Presents Data from the Neratinib Arm of the INSIGhT Trial at t..
CI
11/19Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium..
BU
11/04Puma Biotechnology 3Q-2021 Results Call – Commercial Update
PU
11/04PUMA BIOTECH : Q3 Earnings Snapshot
AQ
11/04PUMA BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
11/04Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
More news
Analyst Recommendations on PUMA BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 245 M - -
Net income 2021 -39,3 M - -
Net cash 2021 25,0 M - -
P/E ratio 2021 -3,74x
Yield 2021 -
Capitalization 134 M 134 M -
EV / Sales 2021 0,45x
EV / Sales 2022 0,52x
Nbr of Employees 267
Free-Float 86,6%
Chart PUMA BIOTECHNOLOGY, INC.
Duration : Period :
Puma Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PUMA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 3,29 $
Average target price 7,83 $
Spread / Average Target 138%
EPS Revisions
Managers and Directors
Alan H. Auerbach Chairman, President, CEO & Secretary
Maximo F. Nougues Chief Financial Officer
Jay M. Moyes Lead Independent Director
Troy E. Wilson Independent Director
Adrian M. Senderowicz Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PUMA BIOTECHNOLOGY, INC.-67.93%134
MODERNA, INC.171.27%114 904
LONZA GROUP AG30.52%59 816
IQVIA HOLDINGS INC.51.92%51 999
SEAGEN INC.-14.61%27 346
CELLTRION, INC.-42.20%24 169